Abstract
Clinical chemistry, immunoassays to remain dominant product groups
The US market for in vitro diagnostic (IVD) products will grow 5.1 percent
annually to $20 billion in 2011. Based on extensive use in pre-hospital
admission screening, basic physical examinations and diabetes self-monitoring,
clinical chemistry will remain the top-selling product group through 2011 and
beyond. However, clinical chemistry diagnostics will generate below-average
growth in demand. While sales of blood glucose test strips will increase at a
strong pace as the number of diabetic patients expands, the market for
clinical chemistry reagents and instruments employed in basic patient
screening will grow slowly due to consolidation in the clinical laboratory
market and decreasing consumable requirements per test.
Established uses in metabolic and infectious disease detection and therapeutic
drug monitoring, coupled with increasing applications in cancer,
cardiovascular disease and congenital marker testing, will keep immunoassays
the second-largest selling IVD product group. However, overall growth
opportunities for immunoassay diagnostics will decelerate over the next decade
due to increasing competition from nucleic acid and cellular analysis testing
products. Competitive and market trends will also weaken growth prospects for
IVD products used in blood testing applications. Advances in immunoassays, PCR
and microarray technologies will moderate gains in demand for hematology
reagents and instruments. Trends toward less invasive surgery will soften
growth prospects for blood banking diagnostics. Improvements in the safety of
anticoagulant and thrombolytic therapies will slow gains in sales of
hemostasis testing products.
View Cart
